Addex Therapeutics Ltd ADXN

ADXN Company Overview

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on the discovery and development of allosteric modulators for neurological disorders and other diseases with significant unmet medical need. The company operates primarily within the biotechnology and central nervous system (CNS) therapeutics industries, with research centered on small-molecule drugs that modulate G protein-coupled receptors (GPCRs). Addex’s platform is designed to develop orally available compounds that selectively regulate receptor activity, a strategy intended to improve efficacy and tolerability compared with traditional receptor-targeting drugs.

The company’s primary value drivers are its proprietary allosteric modulation technology platform, internally developed CNS programs, and strategic partnerships with larger pharmaceutical companies. Addex has historically focused on conditions including Parkinson’s disease, epilepsy, anxiety, and other neurodegenerative or neuropsychiatric disorders. Founded in Switzerland in 2002, the company evolved from an early-stage receptor pharmacology research organization into a publicly traded biotechnology company listed on Nasdaq under the ticker ADXN. Its development strategy has combined internal drug discovery with collaboration-based licensing and co-development arrangements.